HGH Fragment 176-191 vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
HGH Fragment 176-191
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | HGH Fragment 176-191 | Setmelanotide |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 1 mg–3 mg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 12–16 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |
What They Have in Common
HGH Fragment 176-191, Setmelanotide are both commonly used for:
Which Has Stronger Evidence?
- Fat Loss: Setmelanotide has stronger research support.
| Goal | HGH Fragment 176-191 | Setmelanotide |
|---|---|---|
| Fat Loss | medium | high |
Key Studies
Setmelanotide
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.), 2026
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine, 2026
- Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism, 2026
Ready to Learn More?
Looking for trusted sources?